雌激素膜受体GPR30在雌激素相关性肿瘤中的研究进展  

Research Advances in Estrogen Membrane Receptor GPR30 in Estrogen-associated Tumors

作　　者：杨清旭 谢铭 YANG Qingxu;XIE Ming(Department of Gastrointestinal Surgery,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China)

机构地区：[1]遵义医科大学附属医院胃肠外科,贵州遵义563000

出　　处：《医学综述》2020年第6期1078-1085,共8页Medical Recapitulate

基　　金：贵州省科技计划项目(黔科合基础〔2017〕1228)。

摘　　要：雌激素在人体内需要通过与受体结合才能发挥作用,其中与雌激素核受体结合后发挥的基因组效应是雌激素发挥作用的主要方式。此外,雌激素还可通过与雌激素膜受体结合后发挥非基因组效应而发挥作用。G蛋白偶联雌激素受体(GPER/GPR30)作为一种雌激素膜受体,其化学结构、细胞定位、作用方式等与传统的雌激素受体α、β均有显著区别。GPR30广泛参与雌激素介导的多种病理生理反应,并且作为雌激素膜受体参与了雌激素相关性肿瘤的发生、发展。Estrogen needs to bind to the receptor to play an important role in the body,and the genomic effect after the binding to the estrogen nuclear receptor is the main way for estrogen to act.At the same time,studies have shown that estrogen can also play a non-genomic effect by binding to estrogen membrane receptors.G protein-coupled estrogen receptor(GPER/GPR30),as an estrogen membrane receptor,has a significant difference from the traditional estrogen nuclear receptors estrogen receptor α and estrogen receptor β in its chemical structure,cell localization and mode of action.GPR30 is widely involved in a variety of pathophysiological reactions mediated by estrogen,and is involved in the occurrence and development of estrogen-related tumors as a membrane receptor of estrogen.

关 键 词：肿瘤 雌激素核受体 雌激素膜受体 非基因组效应 G蛋白偶联雌激素受体30 

分 类 号：R730.2[医药卫生—肿瘤]